{"id":"leucovorin-calcium-levoleucovorin","safety":{"commonSideEffects":[{"rate":null,"effect":"Allergic sensitization"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Stomatitis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Myelosuppression (when combined with chemotherapy)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leucovorin (folinic acid) and its active L-isomer levoleucovorin bypass the dihydrofolate reductase step and directly provide 5,10-methylenetetrahydrofolate, a critical cofactor for thymidylate synthase and other folate-dependent enzymes. This potentiates the cytotoxic effects of fluorouracil and methotrexate by stabilizing their target enzyme complexes and enhancing DNA synthesis inhibition. Levoleucovorin is the pharmacologically active form, requiring lower doses than the racemic leucovorin calcium.","oneSentence":"Leucovorin calcium and levoleucovorin are reduced folate cofactors that enhance the efficacy of antimetabolite chemotherapy agents by providing essential one-carbon units for nucleotide synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:45.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with fluorouracil)"},{"name":"High-dose methotrexate toxicity rescue"},{"name":"Fluorouracil-based chemotherapy potentiation"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT06750094","phase":"PHASE3","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT07381400","phase":"PHASE2","title":"Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)","status":"NOT_YET_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-01","conditions":"Rectal Cancer","enrollment":128},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT04949256","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-28","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":864},{"nctId":"NCT04060030","phase":"PHASE2","title":"Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism","status":"RECRUITING","sponsor":"Southwest Autism Research & Resource Center","startDate":"2020-10-08","conditions":"Autism Spectrum Disorder, Language Disorders","enrollment":80},{"nctId":"NCT04060017","phase":"PHASE2","title":"Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium","status":"RECRUITING","sponsor":"Southwest Autism Research & Resource Center","startDate":"2020-09-22","conditions":"Autism Spectrum Disorder, Language Disorders","enrollment":80},{"nctId":"NCT04210115","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)","enrollment":703},{"nctId":"NCT03300609","phase":"PHASE3","title":"5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2018-02-27","conditions":"Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Folinic acid"],"phase":"phase_3","status":"active","brandName":"Leucovorin calcium/Levoleucovorin","genericName":"Leucovorin calcium/Levoleucovorin","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Leucovorin calcium and levoleucovorin are reduced folate cofactors that enhance the efficacy of antimetabolite chemotherapy agents by providing essential one-carbon units for nucleotide synthesis. Used for Metastatic colorectal cancer (in combination with fluorouracil), High-dose methotrexate toxicity rescue, Fluorouracil-based chemotherapy potentiation.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}